Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. (Q40117687)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Manel Cascallo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Marta M Alonso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Juan J Rojas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Juan Fueyo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ramon Alemany

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

19 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1607-1615

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17579575%20AND%20SRC:MED&resulttype=core&format=json

The INK4a/ARF network in tumour suppression

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Infection of Mouse Liver by Human Adenovirus Type 5

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

The innate immune response to adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Rat liver slices as a tool to study LPS-induced inflammatory response in the liver.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021

Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300239

7 January 2021